As a venture capital institution and industry incubation platform focused on early stage projects in the field of medical devices, in vitro diagnostic reagents and biotechnology, with the joint efforts of six national experts and teams in the medical device field, including Dr. Zhang Xu, By virtue of its talents and resources, it realizes the common growth of enterprises and capital. The following is an inventory of some work:
1Aishi Medical Technology Chengdu Co., Ltd.
"Aishi Medical" completed the pre-A round of financing of 10 million yuan in August 2017, invested by Guoqian Venture Capital, and completed the 20 million yuan of round A financing in December 2017, led by the Qingzhou Four Seasons Venture Capital Fund.
Founded in September 2016, the company is led by experts from the National "Thousand Talents Program" and is composed of overseas returnees who have long been engaged in artificial intelligence-assisted diagnosis research on fundus diseases. The technology covers the field of fundus disease diagnosis, artificial intelligence based on convolutional neural networks, telemedicine platforms and big data.
In the future, "Aishi Medical" will continue to focus on the "eye fundus disease intelligent replication diagnosis system" series of products, and simultaneously promote online and offline services.
2 Suzhou Xinqing Medical Technology Co., Ltd.
In November 2017, Xinxin Medical completed a pre-A round of financing of RMB 10 million, led by Guoqian Venture Capital, and followed by Hangzhou Taiyu Equity Investment.
The company was founded in July 2017 and is led by Dr. Xu Boling, an expert of the National "Youth Thousand Talents Program", and is composed of a team of people at home and abroad who have been engaged in artificial heart development for a long time. Based on core technologies such as mechatronics, magnetic levitation, and computational fluid dynamics, we are committed to the research and development of short- and medium-term extracorporeal ventricular assist devices (referred to as "short- and medium-term extracorporeal artificial hearts").
China has always lacked effective methods for over-treatment of end-stage heart failure and rescue of acute heart failure, and similar competitive products have not yet entered China. With the economic development, the acceptance of high-value consumables in the Chinese market has also continued to increase. Coupled with the aging population, the national medical device field "import substitution" policy guidance and the current development direction of China's high-value consumables market, "Xinqing Medical" will make great strides forward and develop world-wide, Chinese-made in vitro artificial heart products .
3Nanjing Pu Lijian Biotechnology Co., Ltd.
In April 2018, Nanjing Pu Lijian officially announced the completion of a 8.5 million yuan pre-A round of financing, led by Guo Qian Venture Capital, and Nanjing Huatai Securities Grand Health Fund.
The company was founded in May 2016 by Dr. Li Shuwei, a former associate professor of Maryland State University. He is committed to developing world-class mass spectrometry clinical detection reagents and disease detection services, improving the detection efficiency of various diseases, and integrating research and development, production and synthesis of detection reagents. , Scientific research cooperation and testing market services in one.
Mass spectrometry quantitative detection isotope internal standard is the core raw material of mass spectrometry quantitative detection kit. At present, the market is monopolized by imported products. High-throughput molecular labeling reagents with independent intellectual property rights of the company have been produced for sale. Domestic brands in the field of internal bidding have realized import substitution.
4 Qingpu (Shanghai) Analytical Instruments Co., Ltd.
In July 2018, Qingpu Technology officially announced the completion of 20 million yuan of pre-A round of financing, of which 7.5 million yuan was invested by Guoqian Venture Capital.
The company was founded in February 2017 and is led by Dr. Ouyang Zheng, an expert of the National Thousand Talents Program. Dr. Ouyang Zheng has long been engaged in the development and application of mass spectrometry instruments. He is an expert in mass spectrometry theory, instrument design, sampling and ionization. He is an advocate of miniaturization of international mass spectrometers. A large number of internationally influential contributions have been made in scientific research and practical applications, which are suitable for a series of fields such as food safety, anti-terrorism, medical diagnosis and aerospace exploration. In the future, it will combine the advantages and characteristics of small mass spectrometers to achieve industrialization in target areas.
In the future development process, Guoqian Venture Capital will use its talents and resources to sort out the various segments of the medical device industry, and focus on different industrial chains such as high value-added, high-tech barriers, and import substitution. Thousands of investment areas are focused on layout, and in areas with industrial advantages in China, a highly concentrated ecological industry chain is created through investment and incubation.